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Minimum inhibitory concen-
tration (MIC)Abstract A series of 2-aryl-3-alkanamido-4H-thiazolidin-4-ones were synthesized from long chain
fatty acid hydrazides and studied for their in vitro antibacterial activity. Long chain fatty acid
hydrazides 1 on reaction with different aromatic aldehydes in the presence of catalytic amount of
glacial acetic acid yielded the corresponding aryl hydrazones 2 which on further reaction with thio-
glycolic acid in the presence of anhydrous zinc chloride furnished the title compounds 3. These com-
pounds were characterized by CHN analyses, IR, mass and 1H NMR spectral data. All the
compounds were evaluated for their in vitro antibacterial activity against two Gram positive strains
(Bacillus subtilis and Staphylococcus aureus) and two Gram negative strains (Escherichia coli and
Pseudomonas aeruginosa) and their minimum inhibitory concentration (MIC) were determined.
ª 2011 Production and hosting by Elsevier B.V. on behalf of King Saud University. This is an open access
article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/3.0/).1. Introduction
Infectious diseases are one of the major health problems of the
world population. Certainly, the rapid development of resis-tance to the existing antimicrobial drugs is the root cause of
this global issue. This opens the gate for the medicinal chemists
for the development of novel antimicrobial drugs having a dif-
ferent mechanism of action to combat the problem of multi-
drug resistance (Wise, 2008; Coleman, 2004; Cassell and
Mekalanos, 2001). In a wide variety of heterocyclic structures,
the thiazolidin-4-one nucleus constitutes an important class
displaying a broad spectrum of biological activities (Verma
and Saraf, 2008). Thiazolidin-4-one ring also found in natu-
rally occurring actithiazic acid [() 2-(5-carboxypentyl) (thiaz-
olidin-4-one)] which has been isolated from Streptomyces
strains and exhibited highly speciﬁc in vitro activity against
Mycobacterium tuberculosis (Sobin, 1952). Thiazolidin-4-one
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activities, such as antimicrobial (Ozkirimli et al., 2009; Mul-
wad et al., 2009; Saeed et al., 2007; Vicini et al., 2006; Kavitha
et al., 2006; Mishra et al., 1999), anti-inﬂammatory (Sharma et
al., in press; Deep et al., 2010), anti-HIV (Rao et al., 2004),
anticancer (Guzel et al., 2006), anticonvulsant (Ragab et al.,
1997), etc. It has been found that thiazolidin-4-one nucleus
inhibits the bacterial enzyme MurB, a key enzyme responsible
for the biosynthesis of peptidoglycan (Andres et al., 2000).
Further, derivatives of long chain fatty acid hydrazides have
been reported to possess the biological activity (Rauf et al.,
2008; Awasthi et al., 2007). These reports including our ongo-
ing research program in the ﬁeld of synthesis and antimicrobial
activity of medicinally important compounds (Deep et al.,
2014; Kumar et al., 2011) inspired us to undertake the synthe-
sis of some thiazolidin-4-ones as the novel derivatives of long
chain fatty acid hydrazides. The synthesized compounds were
characterized on the basis of elemental analysis, IR, 1H NMR
and Mass spectral data. All the compounds were screened for
their in vitro antibacterial activity.
2. Results and discussion
2.1. Chemistry
The syntheses of 2-aryl-3-alkanamido-4H-thiazolidin-4-ones
were achieved following the steps outlined in Scheme 1. Alka-
noic acid hydrazides 1 were prepared by the reaction of hydra-
zine hydrate with the corresponding methyl esters of the acids.
The hydrazides 1 then on reﬂuxing with aromatic aldehydes
and 2–3 drops of glacial acid in methanol furnished alkanoic
acid hydrazones 2. Thioglycolic acid reacted with 2 in the pres-
ence of anhydrous zinc chloride to give 3. All the compounds
were obtained in good yield. These compounds were character-
ized on the basis of elemental and spectral analyses. IR spectra
of each compound showed a band for N–H stretching vibra-Scheme 1 Synthesis of 2-aryl-3-alkanamido-4H-thiazolidin-4-
ones.tions near 3340 cm1. The C‚O stretching vibrations of amide
I band were observed in the range of 1636–1650 cm1 while the
amide II, i.e., N–H bending vibrations displayed a band at
about 1550–1557 cm1. The C–H stretching vibrations for al-
kyl chain were observed in the range of 2916–2919 cm1
whereas bending vibrations for methylene scissoring were ob-
served constantly at 1465 cm1. The characteristic methylene
rocking vibrations of the long alkyl chain was observed at
720 cm1.The absorption for aromatic C–H bending vibrations
was observed below 900 cm1. In case of 1H NMR, the chem-
ical shift value for the N–H group was observed in the range of
8.18–8.15 d (ppm) and appeared as singlet (s). Aromatic pro-
tons appeared as multiplet (m) in the assigned value of 7.99–
6.75 d (ppm). The methine proton (S–CH–N) and the methy-
lene protons (S–CH2–C) of the thiazolidinone nucleus
absorbed at 5.98–5.92 d (ppm) and 2.76–2.71 d (ppm), respec-
tively, and appeared as singlets. The methylene protons alpha
to the C‚O group [CO–CH2–CH2–(CH2)n–CH3] appeared
as triplet in the range of 2.28–2.22 d (ppm) whereas the meth-
ylene protons beta to the C‚O group [CO–CH2–CH2–
(CH2)n–CH3] were observed at 1.73–1.67 d (ppm) and ap-
peared as multiplet. The multiplet was also observed at 1.39–
1.22 d (ppm) for the several methylene groups of the long fatty
acyl chain [CO–CH2–CH2–(CH2)n–CH3]. The methyl group of
the long fatty acyl chain appeared as triplet at 0.89–0.85 d
(ppm). All the title compounds showed [M+H]+ of 100%
intensity as the molecular ion peak along with isotopic peak
at [M+2+H]+ of about 4% intensity of the parent ion peak
due to the presence of sulfur atom. Compounds containing
chlorine showed isotopic peak of about 35% intensity whereas
the bromo compounds exhibited isotopic peak of about equal
intensity. The results of elemental analyses were found in good
agreement with the calculated values.
2.2. Antibacterial activity
All the synthesized title compounds were screened for their
in vitro antibacterial activity against two Gram positive
bacterial strains, i.e., Bacillus subtilis (MTCC 121) and Staph-
ylococcus aureus (MTCC 96) and two Gram negative, i.e.,
Escherichia coli (MTCC 40) and Pseudomonas aeruginosa
(MTCC 2453), respectively, and their minimum inhibitory
concentration (MIC) were determined. All the title compounds
were found to be active against all the bacterial strains used in
this study. However, they showed more activity against the
Gram negative than the Gram positive bacterial strains. Out
of the two Gram negative bacterial strains, E. coli (MTCC
40) was found to be more susceptible than P. aeruginosa
(MTCC 2453) against all the title compounds. The minimum
inhibitory concentration (MIC) of the title compounds 3a–p
were found to be 0.65–0.35, 0.70–0.40, 0.85–0.60 and 0.80–
0.60 lg/ml against E. coli (MTCC 40), P. aeruginosa (MTCC
2453), B. subtilis (MTCC 121) and S. aureus (MTCC 96),
respectively. The MICs of the title compounds containing elec-
tron withdrawing groups like ﬂuoro, chloro, bromo or nitro
were found somewhat less than the compounds containing
electron releasing groups like methyl, methoxyl or hydroxyl.
The reference standard ciproﬂoxacin inhibited Gram negative
bacteria viz., E. coli and P. aeruginosa at a MIC of 0.01 and
0.25 lg/ml, respectively, whereas against Gram positive bacte-
ria viz., S. aureus and B. subtilisMIC was found to be 0.15 and
0.12 lg/ml, respectively. The results of the MIC for the stan-
S292 S. Jain et al.dard drug, ciproﬂoxacin, against the bacterial strains used
were found to be within the range as reported in the literature
(Bauernfeind, 1997; Hoogkamp-Korstanje, 1997; Weber et al.,
1988).
3. Experimental
3.1. Chemistry
The purity of all the synthesized compounds were checked by
thin layer chromatography on silica gel G as a stationary phase
and different solvent systems as a mobile phase using iodine
vapors as a detecting agent. Melting points were determined
by the Tempo melting point determination apparatus in open
capillary tubes and are uncorrected. Elemental analyses were
carried out on Carlo Erba1106 CHN Analyzer. Infrared spec-
tra were recorded on Shimadzu 8000 FTIR Spectrophotometer
in KBr phase. Proton NMR spectra were done on Bruker
Avance II 400 NMR Spectrometer using tetramethyl silane
as internal standard. Mass spectra of the compounds were car-
ried out on API-4000 Quadrupole Mass Spectrometer using
electro spray ionization (ESI) technique in positive ion mode.
Long chain fatty acid hydrazides 1a–b and their aryl hydra-
zones 2a–b were prepared according to the procedure de-
scribed in the literature (Yale et al., 1953).
3.2. General procedure for the synthesis of 2-aryl-3-alkanamido-
4H-thiazolidin-4-ones (3a–p)
Alkanoic acid aryl hydrazone (2a–b, 0.01 M) and thioglycolic
acid (0.01 M) were dissolved in dimethyl formamide (50–
60 mL) containing a little quantity of anhydrous zinc chloride
and reﬂuxed for about 6 h. The reaction mixture after cooling
was poured on to crushed ice with vigorous stirring. The pre-
cipitate thus obtained was ﬁltered, washed thoroughly with
cold distilled water, dried and then re-crystallized from etha-
nol. The physical and analytical data of the synthesized title
compounds (3a–p) are given as follows.
3.2.1. 2-Phenyl-3-tetradecanamido-4H-thiazolidin-4-one (3a)
Yield: 87%; m.p.: 90–92 C; IR (KBr, cm-1): 3344 (N–H), 2916
(C–H), 1640 (C‚O), 1550 (N–H), 1465 (CH2), 720 (CH2), 730
& 690 (mono substituted benzene); 1H NMR (DMSO-d6): d
(ppm) 8.17 (s, 1H, NH), 5.98 (s, 1H, S–CH–N), 7.65–7.35
(m, 5H, ArH), 2.74 (s, 2H, S–CH2–C), 2.26 [t, 2H,
CO–CH2–CH2–(CH2)10–CH3], 1.68–1.70 [m, 2H, CO–CH2–
CH2–(CH2)10–CH3], 1.22–1.34 [m, 20H, CO–CH2–CH2–
(CH2)10–CH3], 0.87 (t, 3H, CH3); MS, m/z (%): 405
[M+H]+ (100%), 407 [M+2+H]+ (4%). Anal. Calcd for
C23H36N2O2S: C, 68.27; H, 8.97; N, 6.92. Found: C, 68.15;
H, 8.90; N, 6.84.
3.2.2. 2-(4-Methylphenyl)-3-tetradecanamido-4H-thiazolidin-4-
one (3b)
Yield: 82%; m.p.: 88–89 C; IR (KBr, cm-1): 3346 (N–H), 2916
(C–H), 1636 (C‚O), 1555 (N–H), 1465 (CH2), 830 (p-disubsti-
tuted benzene), 720 (CH2);
1H NMR (DMSO-d6): d (ppm) 8.16
(s, 1H, NH), 5.94 (s, 1H, S–CH–N), 6.97–6.89 (m, 4H, ArH),
2.35 (s, 3H, Ar-CH3), 2.75 (s, 2H, S–CH2–C), 2.27 [t, 2H,
CO–CH2–CH2–(CH2)10–CH3], 1.67–1.69 [m, 2H, CO–CH2–
CH2–(CH2)10–CH3], 1.23–1.35 [m, 20H, CO–CH2–CH2–(CH2)10–CH3], 0.87 (t, 3H, CH3); MS, m/z (%): 419
[M+H]+ (100%), 421 [M+2+H]+ (4%). Anal. Calcd for
C24H38N2O2S: C, 68.86; H, 9.15; N, 6.69. Found: C, 68.71;
H, 9.23; N, 6.62.
3.2.3. 2-(4-Methoxyphenyl)-3-tetradecanamido-4H-thiazolidin-
4-one (3c)
Yield: 85%; m.p.: 80–82 C; IR (KBr, cm-1): 3346 (N–H), 2916
(C–H), 1636 (C‚O), 1555 (N–H), 1465 (CH2), 1250 & 1040
(Ar–OCH3), 830 (p-disubstituted benzene), 720 (CH2);
1H
NMR (DMSO-d6): d (ppm) 8.16 (s, 1H, NH), 5.94 (s, 1H, S–
CH–N), 6.97–6.89 (m, 4H, ArH), 3.82 (s, 3H, OCH3), 2.75
(s, 2H, S–CH2–C), 2.27 [t, 2H, CO–CH2–CH2 (CH2)10–CH3],
1.67–1.69 [m, 2H, CO–CH2–CH2–(CH2)10–CH3], 1.23–1.35
[m, 20H, CO–CH2–CH2–(CH2)10–CH3], 0.87 (t, 3H, CH3);
MS, m/z (%): 435 [M+H]+ (100%), 437 [M+2+H]+ (4%).
Anal. Calcd for C24H38N2O3S: C, 66.32; H, 8.81; N, 6.45.
Found: C, 66.41; H, 8.75; N, 6.52.
3.2.4. 2-(4-Hydroxyphenyl)-3-tetradecanamido-4H-thiazolidin-
4-one (3d)
Yield: 84%; m.p.: 96–98 C; IR (KBr, cm-1): 3420 (O–H), 3345
(N–H), 2916 (C–H), 1638 (C‚O), 1555 (N–H), 1465 (CH2),
1218 (C–O), 832 (p-disubstituted benzene), 720 (CH2);
1H
NMR (DMSO-d6): d (ppm) 10.11 (s, 1H, OH), 8.16 (s, 1H,
NH), 5.96 (s, 1H, S–CH–N), 6.85–6.75 (m, 4H, ArH), 2.72
(s, 2H, S–CH2–C), 2.23 [t, 2H, CO–CH2–CH2–(CH2)10–
CH3], 1.70–1.72 [m, 2H, CO–CH2–CH2–(CH2)10–CH3], 1.24–
1.38 [m, 20H, CO– CH2–CH2–(CH2)10–CH3], 0.87 (t, 3H,
CH3); MS, m/z (%): 421 [M+H]
+ (100%), 423 [M+2+H]+
(4%). Anal. Calcd for C23H36N2O3S: C, 65.68; H, 8.63; N,
6.66. Found: C, 65.76; H, 8.56; N, 6.59.
3.2.5. 2-(4-Chlorophenyl)-3-tetradecanamido-4H-thiazolidin-4-
one (3e)
Yield: 83%; m.p.: 90–92 C; IR (KBr, cm-1): 3344 (N–H), 2918
(C–H), 1640 (C‚O), 1550 (N–H), 1465 (CH2), 1090 (Ar–Cl),
830 (p-disubstituted benzene), 720 (CH2);
1H NMR (DMSO-
d6): d (ppm) 8.15 (s, 1H, NH), 5.97 (s, 1H, S–CH–N),
7.60–7.33 (m, 4H, ArH), 2.71 (s, 2H, S–CH2–C), 2.26 [t, 2H,
CO–CH2–CH2–(CH2)10–CH3], 1.68–1.70 [m, 2H, CO–CH2–
CH2–(CH2)10–CH3], 1.25–1.38 [m, 20H, CO–CH2–CH2–
(CH2)10–CH3], 0.86 (t, 3H, CH3); MS, m/z (%): 439
[M+H] + (100%), 441 [M+2+H] + (35%). Anal. Calcd for
C23H35ClN2O2S: C, 62.92; H, 8.03; N, 6.38. Found: C, 62.81;
H, 8.10; N, 6.29.
3.2.6. 2-(4-Bromophenyl)-3-tetradecanamido-4H-thiazolidin-4-
one (3f)
Yield: 80%; m.p.: 95–97 C; IR(KBr, cm-1): 3340 (N–H), 2917
(C–H), 1642 (C‚O), 1553 (N–H), 1465 (CH2), 1220 (C–O),
830 (p-disubstituted benzene), 720 (CH2);
1H NMR (DMSO-
d6): d (ppm) 8.15 (s, 1H, NH), 5.97 (s, 1H, S–CH–N),
7.60–7.33 (m, 4H, ArH), 2.71 (s, 2H, S–CH2–C), 2.26 [t, 2H,
CO–CH2–CH2–(CH2)10–CH3], 1.68–1.70 [m, 2H, CO–CH2–
CH2–(CH2)10–CH3], 1.25–1.38 [m, 20H, CO–CH2–CH2–
(CH2)10–CH3], 0.86 (t, 3H, CH3); MS, m/z (%): 483
[M+H]+ (100%), 485 [M+2+H]+ (98%). Anal. Calcd for
C23H35BrN2O2S: C, 57.13; H, 7.30; N, 5.79. Found: C,
57.28; H, 7.39; N, 5.71.
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one (3g)
Yield: 81%; m.p.: 77–79 C; IR (KBr, cm-1): 3340 (N–H), 2919
(C–H), 1646 (C‚O), 1553 (N–H), 1465 (CH2), 1233 (Ar–Fl),
830 (p-disubstituted benzene), 720 (CH2);
1H NMR (DMSO-
d6): d (ppm) 8.16 (s, 1H, NH), 5.98 (s, 1H, S–CH–N),
7.65–7.05 (m, 4H, ArH), 2.73 (s, 2H, S–CH2–C), 2.25 [t, 2H,
CO–CH2–CH2–(CH2)10–CH3], 1.67–1.69 [m, 2H, CO–CH2–
CH2–(CH2)10–CH3], 1.25–1.39 [m, 20H, CO–CH2–CH2–
(CH2)10–CH3], 0.87 (t, 3H, CH3); MS, m/z (%): 423
[M+H]+ (100%), 425 [M+2+H]+ (4%). Anal. Calcd for
C23H35FN2O2S: C, 65.37; H, 8.35; N, 6.63. Found: C, 65.28,
H, 8.43; N, 6.69.
3.2.8. 2-(4-Nitrophenyl)-3-tetradecanamido-4H-thiazolidin-4-
one (3h)
Yield: 82%; m.p.: 112–114 C; IR (KBr, cm-1): 3342 (N–H),
2916 (C–H), 1650 (C‚O), 1557 (N–H), 1465 (CH2), 1520 &
1340 (NO2), 830 (p-disubstituted benzene), 720 (CH2);
1H
NMR (DMSO-d6): d (ppm) 8.18 (s, 1H, NH), 5.95 (s, 1H, S–
CH–N), 7.99–7.57 (m, 4H, ArH), 2.76 (s, 2H, S–CH2–C),
2.27 [t, 2H, CO–CH2–CH2–(CH2)10–CH3], 1.68–1.70 [m, 2H,
CO–CH2–CH2–(CH2)10–CH3], 1.24–1.34 [m, 20H, CO–CH2–
CH2–(CH2)10–CH3], 0.87 (t, 3H, CH3); MS, m/z (%): 450
[M+H]+ (100%), 452 [M+2+H]+ (4%). Anal. Calcd for
C23H35N3O4S: C, 61.44; H, 7.85; N, 9.35. Found: C, 61.52;
H, 7.91, N, 9.28.
3.2.9. 2-Phenyl-3-hexadecanamido-4H-thiazolidin-4-one (3i)
Yield: 88%; m.p.:90–92 C; IR (KBr, cm-1): 3348 (N–H), 2917
(C–H), 1644 (C‚O), 1555 (N–H), 1465 (CH2), 720 (CH2), 735
& 690 (mono substituted benzene);1H NMR (DMSO-d6):
d (ppm) 8.16 (s, 1H, NH), 5.97 (s, 1H, S–CH–N) 7.64–7.34
(m, 5H, ArH), 2.73 (s, 2H, S–CH2–C), 2.23 [t, 2H,
CO–CH2–CH2–(CH2)12–CH3], 1.69–1.71 [m, 2H, CO–CH2–
CH2–(CH2)12–CH3], 1.23–1.33 [m, 24H, CO–CH2–CH2–
(CH2)12–CH3], 0.86 (t, 3H, CH3); MS, m/z (%): 433
[M+H]+ (100%), 435 [M+2+H]+ (4%). Anal. Calcd for
C25H40N2O2S: C, 69.40; H, 9.32; N, 6.47. Found: C, 69.49;
H, 9.24; N, 6.53.
3.2.10. 2-(4-Methylphenyl)-3-hexadecanamido-4H-thiazolidin-
4-one (3j)
Yield: 84%; m.p.: 81–83 C; IR (KBr, cm-1): 3344 (N–H), 2918
(C–H), 1640 (C‚O), 1553 (N–H), 1465 (CH2), 832 (p-disubsti-
tuted benzene), 720 (CH2);
1H NMR (DMSO-d6): d (ppm) 8.17
(s, 1H, NH), 5.95 (s, 1H, S–CH–N), 6.97–6.89 (m, 4H, ArH),
2.35 (s, 3H, Ar-CH3), 2.75 (s, 2H, S–CH2–C), 2.26 [t, 2H,
CO–CH2–CH2–(CH2)12–CH3], 1.71–1.73 [m, 2H, CO–CH2–
CH2–(CH2)12–CH3], 1.24–1.36 [m, 24H, CO–CH2–CH2–
(CH2)12–CH3], 0.86 (t, 3H, CH3); MS, m/z (%): 447
[M+H]+ (100%), 449 [M+2+H]+ (4%). Anal. Calcd for
C26H42N2O2S: C, 69.91; H, 9.48; N, 6.27. Found: C, 69.85;
H, 9.42; N, 6.19.
3.2.11. 2-(4-Methoxyphenyl)-3-hexadecanamido-4H-
thiazolidin-4-one (3k)
Yield: 86%; m.p.: 80–82 C; IR (KBr, cm-1): 3344 (N–H), 2918
(C–H), 1640 (C‚O), 1553 (N–H), 1465 (CH2), 1250 & 1040
(Ar–OCH3), 832 (p-disubstituted benzene), 720 (CH2);
1H
NMR (DMSO-d6): d (ppm) 8.17 (s, 1H, NH), 5.95 (s, 1H, S–
CH–N), 6.97–6.89 (m, 4H, ArH), 3.82 (s, 3H, CH3), 2.75 (s,2H, S–CH2–C), 2.26 [t, 2H, CO–CH2–CH2–(CH2)12–CH3],
1.71–1.73 [m, 2H, CO–CH2–CH2–(CH2)12–CH3], 1.24–1.36
[m, 24H, CO–CH2–CH2–(CH2)12–CH3], 0.86 (t, 3H, CH3);
MS, m/z (%): 463 [M+H]+ (100%), 465 [M+2+H]+ (4%).
Anal. Calcd for C26H42N2O3S: C, 67.49; H, 9.15; N, 6.05.
Found: C, 67.57; H, 9.22; N, 6.14.
3.2.12. 2-(4-Hydroxyphenyl)-3-hexadecanamido-4H-
thiazolidin-4-one (3l)
Yield: 85%; m.p.: 96–98 C; IR (KBr, cm-1): 3415 (O–H), 3340
(N–H), 2918 (C–H), 1640 (C‚O), 1550 (N–H), 1465 (CH2),
1218 (C–O), 830 (p-disubstituted benzene), 720 (CH2);
1H
NMR (DMSO-d6): d (ppm) 10.11 (s, 1H, OH), 8.18 (s, 1H,
NH), 5.96 (s, 1H, S–CH–N), 6.85–6.75 (m, 4H, ArH), 2.73
(s, 2H, S–CH2–C), 2.23 [t, 2H, CO–CH2–CH2–(CH2)12–
CH3], 1.69–1.71 [m, 2H, CO–CH2–CH2–(CH2)12–CH3], 1.25–
1.39 [m, 24H, CO–CH2–CH2–(CH2)12–CH3], 0.87 (t, 3H,
CH3); MS, m/z (%): 449 [M+H]
+ (100%), 451 [M+2+H]+
(4%). Anal. Calcd for C25H40N2O3S: C, 66.92; H, 8.99; N,
6.24. Found: C, 66.85; H, 8.89; N, 6.17.
3.2.13. 2-(4-Chlorophenyl)-3-hexadecanamido-4H-thiazolidin-
4-one (3m)
Yield: 84%; m.p.: 90–92 C; IR (KBr, cm-1): 3340 (N–H), 2916
(C–H), 1642 (C‚O), 1555 (N–H), 1465 (CH2), 1090 (Ar–Cl),
830 (p-disubstituted benzene), 720 (CH2);
1H NMR (DMSO-
d6): d (ppm) 8.16 (s, 1H, NH), 5.98 (s, 1H, S–CH–N), 7.60–
7.35 (m, 4H, ArH), 2.71 (s, 2H, S–CH2–C), 2.26 [t, 2H,
CO–CH2–CH2–(CH2)12–CH3], 1.70–1.72 [m, 2H, CO–CH2–
CH2–(CH2)12–CH3], 1.24–1.38 [m, 24H, CO–CH2–CH2–
(CH2)12–CH3], 0.86 (t, 3H, CH3); MS, m/z (%): 467
[M+H]+ (100%), 469 [M+2+H]+ (35%). Anal. Calcd for
C25H39ClN2O2S: C, 64.28; H, 8.42; N, 6.00. Found: C,
64.39; H, 8.51; N, 6.07.
3.2.14. 2-(4-Bromophenyl)-3-hexadecanamido-4H-thiazolidin-
4-one (3n)
Yield: 86%; m.p.: 92–94 C; IR (KBr, cm-1): 3340 (N–H), 2916
(C–H), 1642 (C‚O), 1555 (N–H), 1465 (CH2), 1090 (Ar–Cl),
830 (p-disubstituted benzene), 720 (CH2);
1H NMR (DMSO-
d6): d (ppm) 8.16 (s, 1H, NH), 5.98 (s, 1H, S–CH–N), 7.60–
7.35 (m, 4H, ArH), 2.71 (s, 2H, S–CH2–C), 2.26 [t, 2H,
CO–CH2–CH2–(CH2)12–CH3], 1.70–1.72 [m, 2H, CO–CH2–
CH2–(CH2)12–CH3], 1.24–1.38 [m, 24H, CO–CH2–CH2–
(CH2)12–CH3], 0.86 (t, 3H, CH3); MS, m/z (%): 513
[M+H]+ (100%), 515 [M+2+H]+ (98%). Anal. Calcd for
C25H39BrN2O2S: C, 58.70; H, 7.68; N, 5.48. Found: C,
58.79; H, 7.51; N, 5.59.
3.2.15. 2-(4-Fluorophenyl)-3-hexadecanamido-4H-thiazolidin-
4-one (3o)
Yield: 82%; m.p.: 77–79 C; IR (KBr, cm-1): 3345 (N–H), 2916
(C–H), 1645 (C‚O), 1553 (N–H), 1465 (CH2), 1235 (Ar–F),
830 (p-disubstituted benzene), 720 (CH2);
1H NMR (DMSO-
d6): d (ppm) 8.15 (s, 1H, NH), 5.97 (s, 1H, S–CH–N), 7.63–
7.03 (m, 4H, ArH), 2.75 (s, 2H, S–CH2–C), 2.25 [t, 2H,
CO–CH2–CH2–(CH2)12–CH3], 1.68–1.70 [m, 2H, CO–CH2–
CH2–(CH2)12–CH3], 1.25–139 [m, 24H, CO–CH2–CH2–
(CH2)12–CH3], 0.86 (t, 3H, CH3); MS, m/z (%): 451
[M+H]+ (100%), 453 [M+2+H]+ (4%). Anal. Calcd for
C25H39FN2O2S: C, 66.63; H, 8.72; N, 6.22. Found: C, 66.53;
H, 8.80; N, 6.31.
Table 1 In vitro antibacterial activity of the title compounds (3a–p).
Compound Minimum inhibitory concentration (lg/ml)
B. subtilis (MTCC 121) S. aureus (MTCC 96) E. coli (MTCC 40) P. aeruginosa (MTCC 2453)
3a 0.75 0.80 0.65 0.70
3b 0.75 0.80 0.65 0.70
3c 0.80 0.85 0.65 0.70
3d 0.65 0.70 0.60 0.65
3e 0.60 0.60 0.35 0.35
3f 0.60 0.60 0.35 0.35
3g 0.60 0.60 0.35 0.35
3h 0.60 0.60 0.35 0.35
3i 0.75 0.80 0.65 0.65
3j 0.75 0.80 0.65 0.65
3k 0.80 0.85 0.70 0.75
3l 0.70 0.70 0.60 0.65
3m 0.60 0.60 0.35 0.35
3n 0.60 0.60 0.35 0.35
3o 0.60 0.60 0.35 0.35
3p 0.60 0.60 0.35 0.35
Ciproﬂoxacin (standard drug) 0.12 0.15 0.01 0.25
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Yield: 81%; m.p.: 112–114 C; IR (KBr, cm-1): 3340 (N–H),
2917 (C–H), 1648 (C‚O), 1557 (N–H), 1465 (CH2), 1520 &
1340 (NO2), 830 (p-disubstituted benzene), 720 (CH2);
1H
NMR (DMSO-d6): d (ppm) 8.17 (s, 1H, NH), 5.94 (s, 1H, S–
CH–N), 7.95–7.55 (m, 4H, ArH), 2.76 (s, 2H, S–CH2–C),
2.26 [t, 2H, CO–CH2–CH2–(CH2)12–CH3], 1.69–1.71 [m, 2H,
CO–CH2–CH2–(CH2)12–CH3], 1.24–1.36 [m, 24H, CO–CH2–
CH2–(CH2)12–CH3], 0.87 (t, 3H, CH3); MS, m/z (%): 478
[M+H]+ (100%), 480 [M+2+H]+ (4%). Anal. Calcd for
C25H39N3O4S: C, 62.86; H, 8.23; N, 8.80. Found: C, 62.77;
H, 8.31; N, 8.88.3.3. Antibacterial activity
All the title compounds were screened for their in vitro antibac-
terial activity against two Gram positive strains, i.e.,B. subtilis
(MTCC 121) and S. aureus (MTCC 96) and two Gram nega-
tive strains, i.e., E. coli (MTCC 40) and P. aeruginosa (MTCC
2453), respectively. Ciproﬂoxacin was used as the standard
drug for the present study. Serial two-fold dilution technique
was used for the study of antibacterial activity (Cappucino
and Sherman, 1999). A stock solution (10 lg/ml) of all the title
compounds and standard drug was prepared in dimethyl sulf-
oxide. Sterilized double strength nutrient broth (DSNB) was
used as a growth media. The stock solution was serially diluted
by DSNB aseptically to give concentrations of 5.0–0.01 lg/ml
into a series of sterilized culture tubes. All the tubes were inoc-
ulated by bacterial strain. The inoculum’s size was approxi-
mately 106 colony forming units (CFU/ml). The inoculated
tubes were incubated for 24 h at 37(±1) C. After 24 h, the
inoculated culture tubes were macroscopically examined for
turbidity. The culture tube showing turbidity (lower concentra-
tion) and the culture tube showing no turbidity (higher concen-
tration) gave the minimum inhibitory concentration (MIC) forthe compound. The MIC for the title compounds and the stan-
dard drug, i.e., ciproﬂoxacin is presented in Table 1.
4. Conclusion
Present study describes the synthesis of a series of 2-aryl-3-
alkanamido-4H-thiazolidin-4-ones starting from the hydra-
zides of the long chain fatty acids. The compounds were
characterized by modern analytical techniques, such as
CHN analyses, IR, Mass and proton NMR spectra. All
the title compounds were screened for their in vitro antibac-
terial activity against B. subtilis, S. aureus (Gram positive)
and E. coli, P. aeruginosa (Gram negative) and their mini-
mum inhibitory concentration (MIC) were determined. The
results of antibacterial activity showed that compounds con-
taining electron withdrawing groups, e.g., chloro, bromo,
ﬂuoro or nitro were found to be more active than the com-
pounds containing electron releasing groups such as methyl,
methoxyl or hydroxyl. These results suggest that some more
compounds using different aromatic or hetero-aromatic alde-
hydes and fatty acids should be synthesized and screened for
their antibacterial activity to explore the possibility of 2-aryl-
3-alkanamido-4H-thiazolidin-4-ones as a novel series of
antibacterials.Acknowledgments
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